Treating psoriatic arthritis: how effective are TNF antagonists?

PubWeight™: 0.83‹?›

🔗 View Article (PMC 2833458)

Published in Arthritis Res Ther on June 21, 2004

Authors

Alice B Gottlieb1, Christian E Antoni

Author Affiliations

1: Clinical Research Center UMDNJ-RWJ Medical School, New Brunswick, NJ, USA. alice.gottlieb@umdnj.edu

Articles cited by this

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 6.49

The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol (2000) 3.62

Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med (1987) 2.80

Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther (2002) 2.58

The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol (2002) 2.40

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum (2002) 2.35

The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol (2002) 2.15

Patterns of cytokine production in psoriatic synovium. J Rheumatol (1998) 1.72

HLA antigens in psoriatic arthritis. J Rheumatol (1986) 1.69

Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol (1995) 1.68

Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol (1997) 1.65

Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol (1994) 1.57

Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum (2002) 1.46

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Psoriatic arthritis. Rheum Dis Clin North Am (1998) 1.15

Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol (1999) 1.12

Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol (1999) 1.05

Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol (1995) 0.99

Psoriatic arthritis. Genetics and HLA antigens. Baillieres Clin Rheumatol (1994) 0.98

The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum (1995) 0.97

A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol (2001) 0.93

Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med (1995) 0.92

Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol (2001) 0.91

Photochemotherapy and psoriatic arthritis. A prospective study. Ann Intern Med (1979) 0.90

Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int (2002) 0.87

Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study. Br J Dermatol (1996) 0.83

Immunomodulating drugs in the management of psoriatic arthritis. Am J Clin Dermatol (2001) 0.77